Butterfly Skin Therapy Pipeline Primed For Transformation
As Amryt's Oleogel-S10 Gets Priority Review
Executive Summary
No drugs are approved for epidermolysis bullosa and children with so-called butterfly skin are currently treated by cleaning open wounds and bandaging them. This could soon change.
You may also be interested in...
US FDA’s Botanical Drugs Guidance Will See Rare Outing For Amryt’s Filsuvez NDA
Amryt’s birch bark extract oleogel-S10 for Epidermolysis Bullosa patients might become only the third botanical drug to clear the FDA.
T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
UCB And Analysts Believe Bimekizumab Will Be Super-Blockbuster
The psoriasis market is a tough one for bimekizumab to crack but UCB head of immunology Emmanuel Caeymaex believes the clinical package and investment in promotion will see the IL-17A and IL-17F inhibitor topple its rivals.